Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic
Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines
Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors
Marengo Therapeutics Announces Formation of Scientific Advisory Board to Advance the Company's Development of Novel Therapeutics for Precision Immuno-Oncology
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer
Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)
Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting
Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors
Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Marengo Therapeutics to Participate in Investor, Scientific, Industry Conferences
Apple Tree Partners Donates to Humanitarian Relief Efforts in Ukraine
ATP Statement on War in Ukraine
Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007
Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx® System for Chronic Bronchitis
Intergalactic Therapeutics Announces Scientific Advisory Board Membership
Nine Square Therapeutics Appoints Robert Paul as CEO
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference
ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A
Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting
Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Nereid Therapeutics Announces Scientific Advisory Board Membership
Nereid Therapeutics Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors
ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding
Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ATP Founds New Center for CRISPR Target Discovery in Collaboration with Innovative Genomics Institute (IGI) and Jennifer Doudna
Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
Galaxy Medical Enrolls First Patients in SPACE-AF Study
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
RNA: From the Messenger to the Medicine (Endpoints News Biotech Voices editorial by Stoke CEO Ed Kaye)
Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
Nine Square: Taking Aim at Organelle Function in Movement Disorders with Computation and Imaging (BioCentury Emerging Company Profile)
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
Breathing Life into Britain’s Life-Sciences Industry (The Economist)
Stoke Presents New Data That Demonstrate Tango Antisense Oligonucleotides Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Doug Godshall to Chair Gala Therapeutics Board of Directors
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
ATP Forms ATP V With $1 Billion in New Capital Commitments
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field
First Patients Treated with Galaxy Medical’s CENTAURI™ Pulsed Electric Field Cardiac Ablation System
Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress
Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis
Preclinical Data on Stoke Therapeutics' STK-001 Published in Science Translational Medicine
Four Questions for Neurology Startups as Venture Investors Pour Millions into the Field (STAT News)
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Apple Tree Partners Founds Nine Square Therapeutics to Pioneer Novel Treatments for Movement Disorders
Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk
Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx™ System for Chronic Bronchitis
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis
Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
U.S. District Court Orders FDA to Reconsider Application for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Alexion Completes Acquisition Of Syntimmune